浙江海翔药业股份有限公司 2023年度独立董事述职报告（钱建民） 作为浙江海翔药业股份有限公司(以下简称"公司")的第七届董事会独立董 事，本人严格按照《公司法》、《上市公司独立董事管理办法》等相关法律法规 和《公司章程》、《独立董事工作制度》的规定和要求，诚信、勤勉、独立地履 行职责，积极关注公司的经营业务及发展情况，切实维护公司整体利益以及全体 股东特别是中小股东的合法权益，本人现就2023年度独立董事履职情况述职如下： 一、基本情况 本人钱建民，中国国籍，无境外永久居留权，生于1958年1月，医学博士学 位，中国致公党党员。1987年参加工作，曾任职于江苏省人民医院肝胆外科主任， 复旦大学附属华山医院肝病中心副主任，肝移植中心主任，教授、博士生导师。 现担任海泽临床成果转化医学研究院（无锡）有限公司执行董事、CEO。2022年 11月30日起担任公司独立董事。 报告期内，本人任职情况均符合《上市公司独立董事管理办法》第六条规定 的独立性要求，不存在影响独立性的情况。 二、年度履职概况 （一）出席会议的情况 1、出席董事会及股东大会情况 2023年度，公司共召开6次董事会会议，1次股东大会。本人出席会议情 ...

证券代码：002099 证券简称：海翔药业 公告编号：2024-017 浙江海翔药业股份有限公司 第七届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）第七届董事会第九次会 议于 2024 年 4 月 16 日以电子邮件形式发出通知，于 2024 年 4 月 26 日以现场 加视频方式在公司会议室召开，会议应出席董事 8 人，实际出席董事 8 人，其 中，王扬超先生、许国睿先生、姚冰先生、陶红女士、王晓洋女士、俞永平先 生、钱建民先生出席现场会议，梁超女士以视频方式参会，公司监事、高级管 理人员列席会议。会议召开符合《公司法》及《公司章程》的规定，合法有 效。会议由董事长王扬超先生主持，经过与会董事的充分讨论，会议审议通过 了如下议案： 一、审议通过了《2023 年度董事会工作报告》 表决结果：同意票 8 票，反对票 0 票，弃权票 0 票。 内容详见巨潮资讯网《2023 年度董事会工作报告》。 公司独立董事俞永平先生、钱建民先生、梁超女士向董事会提交了《2023 年度独立董事述职报告》，并 ...

独立董事年报工作制度 （2024 年 4 月修订） 第一条 为了进一步完善浙江海翔药业股份有限公司（以下简称"公司"）的 治理机制，加强内部控制建设，加强信息披露文件编制工作的基础，充分发挥独 立董事在年报编制和披露方面的监督作用，根据《中华人民共和国公司法》、《上 市公司独立董事管理办法》、《深圳证券交易所股票上市规则》及《浙江海翔药业 股份有限公司章程》（以下简称"《公司章程》"）等有关规定，结合公司年报编制 和披露实际情况，特制定本工作制度。 第二条 独立董事应在公司年报编制和披露过程中，按照有关法律、行政法 规及《公司章程》等相关规定，切实履行独立董事的责任和义务，勤勉尽责的开 展工作，维护公司整体利益。 浙江海翔药业股份有限公司 第三条 独立董事应认真学习中国证券监督管理委员会（以下简称"中国证 监会"）、深圳证券交易所等监管部门关于年报编制和披露的工作要求，积极参加 其组织的培训。 第四条 每个会计年度结束后两个月内，公司管理层应当向独立董事汇报公 司本年度的生产经营情况和投、融资活动等重大事项的进展情况，公司财务负责 人应当向独立董事汇报本年度的财务状况和经营成果情况。公司管理层应安排独 立董事 ...

股票代码：002099 股票简称：海翔药业 公告编号：2024-031 浙江海翔药业股份有限公司 关于举行 2023 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）于 2024 年 4 月 29 日披露 了2023年年度报告。为了让广大投资者能进一步了解公司2023年度的经营情况， 公司将于 2024 年 5 月 13 日下午 15:00 至 17:00 在深圳证券交易所互动易平台举 办 2023 年度业绩说明会，与投资者进行沟通交流，听取投资者的意见和建议。 本次业绩说明会将采用网络远程方式举行，投资者可登录深圳证券交易所互动易 平台（http://irm.cninfo.com.cn）进入"云访谈"栏目参与本次业绩说明会。 公司出席本次业绩说明会的人员有：公司董事长王扬超先生、总经理许国睿 先生、财务总监姚冰先生、董事会秘书王晓洋女士、独立董事俞永平先生、独立 董事钱建民先生、独立董事梁超女士。（如有特殊情况，参与人员会有调整） 为充分尊重投资者、提升交流的针对性，现就公司 2023 年 ...

Financial Performance - The company's revenue for Q1 2024 was ¥528,463,890.64, a decrease of 16.65% compared to ¥634,047,833.60 in the same period last year[7] - Net profit attributable to shareholders was ¥32,593,338.56, down 22.58% from ¥42,101,946.61 year-on-year[7] - Total operating revenue for Q1 2024 was $528.46 million, a decrease of 16.66% from $634.05 million in the same period last year[37] - Net profit for Q1 2024 was $32.10 million, down 23.4% compared to $41.85 million in Q1 2023[41] - Total comprehensive income attributable to the parent company was ¥32,593,338.56, down from ¥42,101,946.61 in the previous period, representing a decrease of approximately 22.5%[43] Cash Flow - The net cash flow from operating activities was ¥28,489,229.96, representing a significant decline of 82.13% from ¥159,451,304.75 in the previous year[7] - Cash inflow from operating activities totaled ¥440,566,222.35, down 11.4% from ¥497,507,810.56 in the previous period[44] - Cash outflow from operating activities increased to ¥412,076,992.39, compared to ¥338,056,505.81 in the previous period, marking a rise of 21.9%[44] - Net cash flow from investing activities was -¥58,747,912.25, a decline from a positive cash flow of ¥81,685,962.84 in the previous period[46] - Cash inflow from financing activities increased to ¥1,175,600,000.00, up from ¥966,107,488.00 in the previous period, reflecting a growth of 21.6%[46] - Cash outflow from financing activities rose to ¥938,615,931.61, compared to ¥362,399,978.71 in the previous period, indicating an increase of 159.2%[46] - The ending balance of cash and cash equivalents was ¥1,459,324,838.28, down from ¥1,869,798,598.82 in the previous period, a decrease of approximately 22%[46] Assets and Liabilities - The total assets at the end of the reporting period were ¥7,650,432,164.42, an increase of 1.73% from ¥7,520,092,953.12 at the end of the previous year[7] - Total liabilities rose to $2.11 billion, compared to $1.92 billion in the previous year, indicating a growth of 10.5%[36] - The company's equity attributable to shareholders decreased by 1.16% to ¥5,541,569,876.91 from ¥5,606,352,298.36[7] - The company maintained a stable equity position with total equity at $5.54 billion, slightly down from $5.61 billion[36] Shareholder Information - Total number of common shareholders at the end of the reporting period is 30,172[18] - Zhejiang Donggang Industrial Co., Ltd. holds 32.37% of shares, totaling 523,982,587 shares[22] - Wang Yunfu, a natural person, holds 7.34% of shares, totaling 118,800,000 shares, with 38,000,000 shares pledged[22] - As of March 31, 2024, the company has repurchased 21,874,798 shares, accounting for 1.3514% of total share capital[27] - The total amount for the share repurchase plan is between RMB 150 million and RMB 300 million, with a maximum repurchase price of RMB 8.92 per share[26] - The chairman, Wang Yangchao, has increased his holdings by 696,500 shares, accounting for 0.0430% of total shares[26] Operational Metrics - The basic and diluted earnings per share remained unchanged at ¥0.02[7] - Non-recurring gains and losses totaled -¥663,358.00, primarily due to foreign exchange hedging losses[8] - The company reported a significant increase in prepayments by 74.96%, amounting to ¥38,986,801.14 compared to ¥22,283,130.66 in the previous year[13] - The company experienced a 92.63% reduction in trading financial liabilities, decreasing to ¥2,682,000.00 from ¥36,370,389.61[13] - Accounts receivable increased to RMB 477,138,467.57 from RMB 424,703,017.66[29] - Inventory decreased to RMB 636,368,872.33 from RMB 702,270,769.40[29] - The company reported a significant increase in research and development expenses, totaling $30.01 million, compared to $31.04 million in the previous year[37] - Investment income showed a loss of $6.03 million, contrasting with a gain of $20.09 million in the prior year[41] Strategic Initiatives - The company is focusing on market expansion and new product development as part of its strategic initiatives moving forward[39] - The company plans to continue its share repurchase based on market conditions within the specified period[27] Audit Information - The company did not undergo an audit for the first quarter report[48]

浙江海翔药业股份有限公司 股东大会议事规则 （2024 年 4 月修订） 第一章 总则 第一条 为保证浙江海翔药业股份有限公司（以下简称"公司"）股东大会的 正常秩序和决议的合法性，提高股东大会议事效率，维护全体股东的合法权益， 依据《中华人民共和国公司法》（下简称"《公司法》"）、《上市公司股东大会规则》 （下简称"《股东大会规则》"）、《上市公司治理准则》（下简称"《治理准则》"） 及《浙江海翔药业股份有限公司章程》（以下简称"《公司章程》"）的有关规定， 制定本议事规则。 第二条 公司应当严格按照法律、行政法规、本规则及公司章程的相关规定 召开股东大会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东大会。公司全体董事应 当勤勉尽责，确保股东大会正常召开和依法行使职权。 第三条 股东大会由公司全体股东组成，是公司的最高权力机构。股东大会 应当在《公司法》和《公司章程》规定的范围内依法行使下列职权： （一）选举和更换董事、监事，决定有关董事、监事的报酬事项； （二）审议批准董事会的报告； （三）审议批准监事会的报告； （四）审议批准公司的利润分配方案和弥补亏损方案； （五）对公司 ...

浙江海翔药业股份有限公司 2023年度内部控制自我评价报告 浙江海翔药业股份有限公司全体股东： 根据《企业内部控制基本规范》及《深圳证券交易所上市公司自律监管指引 第1号——主板上市公司规范运作》等内部控制监管要求（以下简称企业内部控 制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部 控制日常监督和专项监督的基础上，我们对公司截至2023年12月31日（内部控制 评价报告基准日）的内部控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性，故仅能为实现上述目标提供合理保证。此外，由于 ...

证券代码：002099 证券简称：海翔药业 公告编号：2024-032 浙江海翔药业股份有限公司 浙江海翔药业股份有限公司（以下简称"公司"）已于2024年4月29日披露 了2023年年度报告，为便于广大投资者深入全面地了解公司情况，公司将举办投 资者接待日活动，现将有关事项公告如下： 一、接待时间 2024年5月20日下午15:00-17:00。 二、接待地点 浙江省台州市椒江区岩头工业区海虹路71号台州前进会议室 三、预约方式 欲参与本次投资者接待日活动的投资者请于2024年5月15日前与公司投资发 展部联系，以便接待登记和安排。 联系人：蒋如东 关于举办投资者接待日的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四、公司参与人员 董事长王扬超先生，总经理许国睿先生，财务总监姚冰先生，董事会秘书王 晓洋女士（如有特殊情况，参与人员会有调整）。 五、注意事项 浙江海翔药业股份有限公司 电 话：0576-89088166 传 真：0576-89088128 邮 箱：stock@hisoar.com 地 址：浙江省台州市椒江区岩头工业区海虹路71号公司投 ...

海翔药业公司章程 浙江海翔药业股份有限公司 公司章程 （2024 年 4 月修订） 1 海翔药业公司章程 目 录 2 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第四章 股东及股东大会 第一节 股东 第二节 股东大会的一般规定 第三节 股东大会的召集 第四节 股东大会的提案与通知 第五节 股东大会的召开 第六节 股东大会的表决和决议 第五章 董事会 第一节 董事 第二节 董事会 第六章 总经理及其他高级管理人员 第七章 监事会 第一节 监事 第二节 监事会 第八章 财务会计制度、利润分配和审计 第一节 财务会计制度 第二节 内部审计 第三节 会计事务所的聘任 第九章 通知和公告 第一节 通知 第二节 公告 海翔药业公司章程 第十章 合并、分立、增资、减资、解散和清算 第一节 合并、分立增资和减资 第二节 解散和清算 3 第十一章 修改章程 第十二章 附则 海翔药业公司章程 第一章 总 则 第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行为，根据 《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简 称 ...

Financial Measurement and Reporting - The company measures financial assets and liabilities at fair value, with changes recognized in profit or loss for financial liabilities designated at fair value[1]. - Financial liabilities are subsequently measured at fair value, with gains or losses from changes in credit risk recognized in other comprehensive income[1]. - The company uses expected credit losses to assess impairment for financial assets measured at amortized cost and certain other financial instruments[6]. - The expected credit loss rates for accounts receivable are based on historical loss experience and future economic forecasts, with rates of 5% for up to 1 year, 30% for 1-2 years, 80% for 2-3 years, and 100% for over 3 years[11]. - The company applies a single financial instrument or portfolio basis to assess expected credit risk and measure expected credit losses[9]. - The company recognizes cumulative changes in expected credit losses for credit-impaired financial assets only from the date of initial recognition[7]. - The company will remeasure the remaining equity at fair value on the date of losing control over the subsidiary, with the investment income recognized in the current period[22]. - The company recognizes contract assets or liabilities based on the relationship between fulfilling obligations and customer payments, netting them in the balance sheet[46]. - Employee compensation liabilities are recognized based on the best estimate of expenditures required to fulfill current obligations[51]. - The company will account for share-based payments, both equity-settled and cash-settled, in accordance with relevant accounting standards[52]. Inventory and Asset Management - Inventory is measured at the lower of cost and net realizable value, with provisions for inventory write-downs recognized when costs exceed net realizable values[15]. - The company's raw materials have a book balance of ¥184,930,123, with a provision for inventory impairment of ¥24,970,003.6, resulting in a net book value of ¥159,960,120[60]. - The total inventory balance is ¥823,197,836, with an impairment provision of ¥120,927,066, leading to a net book value of ¥702,270,769[60]. - The company’s inventory includes work-in-progress valued at ¥38, with a provision for impairment of ¥6, indicating ongoing production activities[60]. - The company has established a sound inventory management system to mitigate risks associated with inventory shortages and excesses, ensuring stable and healthy development[199]. Revenue Recognition and Financial Performance - The company recognizes revenue based on the progress of performance obligations, with revenue confirmed upon the transfer of control of goods to customers[56]. - The company’s sales of raw pharmaceutical materials and intermediates are recognized at the point of delivery to the buyer for domestic sales and upon customs clearance for exports[59]. - The company reported a total revenue for the year was approximately ¥2.17 billion, a decrease from ¥2.70 billion in the previous year, representing a decline of about 19.7%[81]. - The net profit attributable to shareholders for the first quarter was approximately ¥42.10 million, while the second quarter showed a loss of ¥22.93 million, indicating significant volatility in earnings[81]. - The company reported a net profit loss of approximately ¥381.47 million in the fourth quarter, highlighting ongoing financial challenges[81]. - The revenue for the first quarter was approximately ¥634.05 million, while the fourth quarter revenue was approximately ¥495.26 million, showing a downward trend throughout the year[81]. - The company’s direct sales model generated revenue of CNY 2,171,886,860, down 19.68% year-over-year, with a gross margin of 14.03%[141]. Investment and Capital Expenditure - The company determines the initial investment cost for business combinations based on the fair value of the consideration paid on the acquisition date[17]. - Borrowing costs can be capitalized when certain conditions are met, including the occurrence of asset expenditures and borrowing costs[26]. - If the construction or production of capitalizable assets is interrupted for more than three months, capitalization of borrowing costs will be suspended[33]. - The total investment amount for the reporting period was ¥345,483,319.56, a decrease of 65.22% compared to ¥993,398,708.20 in the same period last year[176]. - The company has committed a total investment of CNY 40,000 million for the Active Pharmaceutical Ingredients (API) and intermediates CMO center expansion project, with an adjusted total investment of CNY 28,440.36 million, achieving an investment progress of 102.85%[191]. - The pharmaceutical comprehensive R&D center project has an adjusted total investment of CNY 6,875.87 million, with a 100% investment progress achieved[191]. - The company has invested CNY 1,237.1 million in the headquarters research institute project, achieving an investment progress of 11.73%[191]. - The environmental protection facility renovation project has an adjusted total investment of CNY 14,000 million, with an investment progress of 105.75%[191]. Market and Strategic Developments - The company has established a strategic partnership with Boehringer Ingelheim, resulting in a doubling of orders compared to the previous year[120]. - The global pharmaceutical market is projected to grow at an annual rate of 3%-6%, reaching $1.9 trillion by 2027, providing growth opportunities for the company[123]. - The company is focusing on high-performance environmentally friendly dyes, with a product line that includes reactive blue dyes known for their superior performance[122]. - The domestic dye industry is facing challenges with reduced demand and increased competition, necessitating a focus on high-quality development strategies[124]. - The company is actively pursuing the development of functional dyes and specialty pigments to address high-quality development constraints in the industry[125]. - The company aims to enhance its capabilities in contract manufacturing and development services (CMO/CDMO) to capture opportunities in clinical phases II and III[120]. - The company is committed to integrating green and intelligent development in its dye and pigment production processes to align with national industrial policies[124]. - The company is actively expanding its international market presence, with significant sales in the US, Europe, Japan, and India[129]. Research and Development - Direct costs related to research and development activities include materials, fuel, and maintenance of equipment used in R&D[37]. - R&D investment amounted to 115.56 million yuan, representing 5.32% of total revenue, with 342 R&D personnel[135]. - The company has submitted 6 new patent applications and received 4 patent grants during the reporting period[135]. Financial Position and Liabilities - Cash and cash equivalents at the end of the period were CNY 1,420,570,794.77, representing 18.89% of total assets[172]. - Accounts receivable at the end of the period amounted to CNY 424,703,017.66, accounting for 5.65% of total assets[172]. - Inventory at the end of the period was CNY 702,270,769.40, representing 9.34% of total assets, with a decrease attributed to inventory impairment[172]. - The total amount of short-term borrowings was CNY 8,610,000, accounting for 13.68% of total liabilities[172]. - The total amount of long-term borrowings decreased significantly due to repayments during the period[172]. - The company's financial assets totaled ¥537,441,287.63, with a decrease of ¥72,940,597.78 during the reporting period[174]. - The company's financial liabilities amounted to ¥23,480,126.06, with an increase of ¥32,024,589.60 during the reporting period[174]. - The total amount of pledged bank acceptance bills at the end of the period was CNY 400,383,446.04[159]. - The total amount of other receivables written off during the period was CNY 22,728,178.50, accounting for 51.00% of the total other receivables[162]. - The total bad debt provision amounted to CNY 20,437,512.26, representing 100% of the expected credit loss model for the first stage[157]. Compliance and Governance - The company has no discrepancies in net profit and net assets between international accounting standards and Chinese accounting standards during the reporting period[111]. - The company’s major accounting firm is Tianjian Accounting Firm, which is responsible for auditing its financial statements[79]. - The independent directors support the company's foreign exchange hedging activities, emphasizing that they are closely related to the company's operational needs and do not involve speculative risks[66]. - The company disclosed an ESG report for the first time, highlighting achievements in environmental protection, employee rights, and social responsibility[138].